Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10957514 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5032551 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9400 | 1.00 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1333521 | 0.97 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9129 | 0.97 | — | — | |
| SCHEMBL11399499 | 0.95 | HRH3 (0.59) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3191128 | 0.95 | HRH3 (0.67) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20303711 | 0.94 | HRH3 (0.57) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| Water SCHEMBL30636156 | 0.94 | HRH3 (0.57) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4504898 | 0.92 | HRH3 (0.70) | HRH3CYP1A2MAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | claimed |
| US-7973164-B2 | Quinoline derivatives | ASTRAZENECA AB (SE) | 2011-07-05 | — | — | US | claimed |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| US-20090076075-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | claimed |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | claimed |
| US-20090036485-A1 | Quinoline derivatives | JUNG FREDERIC HENRI | 2009-02-05 | — | — | US | claimed |
| EP-1994023-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| EP-1994028-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | claimed |
| WO-2003008409-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-30 | — | — | WO | claimed |
| WO-2002092578-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002092577-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | claimed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | claimed |
| WO-2002016352-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-02-28 | — | — | WO | claimed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | claimed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | claimed |
| US-4483833-A | DESULFURIZATION | EXXON RESEARCH & ENGINEERING CO. (US) | 1984-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076075-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, NRAS | HRH3 228/4885CYP1A2 483/4885MAPK1 602/4885 |
| US-20090036485-A1 | Quinoline derivatives | AQP3, PGF, AQP1 | HRH3 149/4885CYP1A2 529/4885MAPK1 1445/4885 |
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | RECQL, NQO2, NRAS | HRH3 373/4885CYP1A2 519/4885MAPK1 877/4885 |
| US-20090233950-A1 | QUINAZOLINE DERIVATIVES | NQO2, CCNI, F12 | HRH3 169/4885CYP1A2 546/4885MAPK1 500/4885 |
| US-20090076074-A1 | QUINOLINE DERIVATIVES | RECQL, NQO2, CCNA1 | HRH3 269/4885CYP1A2 369/4885MAPK1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.